FILSPARI's dual-indication launch drives 71% revenue growth, but scaling into FSGS and defending against emerging IgAN entrants is the proof point

Travere Therapeutics is a commercial-stage company whose lead product, a targeted kidney disease drug called FILSPARI, is approved to treat two rare glomerular conditions and generated $161 million in U.S. sales in the second quarter of 2026.

FILSPARI (sparsentan), a dual endothelin and angiotensin receptor antagonist, generated $161M in U.S. net product sales in Q2 2026, the quarter after its FSGS approval, confirming commercial traction across two rare kidney indications. The thesis holds if FILSPARI sustains share in IgAN while capturing FSGS patients before complement- and immune-targeted entrants establish clinical differentiation. The primary risk is pipeline-level: a $112.5M upfront license for civorebrutinib, an early-stage BTK inhibitor, signals the company views organic R&D as insufficient to sustain growth beyond sparsentan.